Overview
Supernus Pharmaceuticals is a specialty CNS biopharmaceutical company with a portfolio of approved products for epilepsy, ADHD, and Parkinson's disease, including Oxtellar XR, Trokendi XR, Qelbree, and Gocovri. They focus on developing differentiated medicines for underserved neurological conditions.
More in Neuropharmaceuticals
Latest industry news
FDA Grants De Novo Approval to Modius Spero, Clearing First Neuromodulation Device for PTSD
2026-09-03 · Policy
Butterfly Network's BCI Chip Licensing Deal Rattles Investors as Shares Drop Nearly 10%
2026-09-02 · Industry
Merge Labs and Butterfly Network Unite to Push Ultrasound-Based BCIs Into the Mainstream
2026-09-01 · Industry
FDA Grants CorTec Second Breakthrough Device Designation for Its Brain-Computer Interface
2026-08-31 · Policy
Company details
Category
💊 Neuropharmaceuticals
Location
Rockville, USA
Funding
Public · NASDAQ: SUPN
Website
www.supernus.comListed
2026-06-15
Is this your company?
Claim this listing to add your logo, full description, team, and products. Premium listings get featured placement.
Claim & upgrade listingAdvertise
Reach neurotech professionals
Newsletter sponsorships, featured listings, and sponsored articles.
View packages →